Ranibizumab recalls

The FDA has published 2 recalls involving Ranibizumab since 2012. The latest was reported on 9 Nov 2022. Most were for sterility. Genentech has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.

Total recalls2since 2012

Last 12 months0reported

Class I00% of total

Ongoing0latest 9 Nov 2022

Recalls per month, last 24 months

click a bar for that month

0Nov '24 0 0 0Feb 0 0 0May 0 0 0Aug 0 0 0Nov 0 0 0Feb 0 0 0May 0 0 0Aug 0 0

Severity split

Class I 0 0%Class II 1 50%Class III 1 50%

Why ranibizumab is recalled

Sterility150%
Other Reasons150%

Companies

By year

2022150%
2012150%

All ranibizumab recalls, newest first

2 total

Reported	Class	Recall	Company	Reason	Where
9 Nov 2022Drug	CLASS III	Susvimo (ranibizumab injection), 100mg/mL recalled by GenentechSusvimo	Genentech	Other	Nationwide
22 Aug 2012Drug	CLASS II	Ranibizumab, Sdpf - Syringe, 5/16") 10mg/ML Injectable recalled	Franck's Lab Inc., d.b.a. Franck's Compounding Lab	Sterility	Nationwide

Should you stop taking Ranibizumab?

Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.